Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2003-03-31

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vascular responses to angiotensin II and histamine are compared before and after 30 days of systemic treatment with either irbesartan 150 mg or atorvastatin 20 mg.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vascular responses to angiotensin II and histamine are compared before and after 30 days of systemic treatment with either irbesartan 150 mg or atorvastatin 20 mg.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subjects

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

venoconstriction venodilation pleiotropic effects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

atorvastatin

Intervention Type DRUG

irbesartan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy subjects
* no relevant disease
* amendment: hypercholesterolaemic subjects

Exclusion Criteria

* any relevant disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wilhelm Kirch, MD

Role: STUDY_CHAIR

Institute of Clinical Pharmacology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Clinical Pharmacology, Medical Faculty, University of Technology

Dresden, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Schindler C, Guenther K, Hermann C, Ferrario CM, Schroeder C, Haufe S, Jordan J, Kirch W. Statin treatment in hypercholesterolemic men does not attenuate angiotensin II-induced venoconstriction. PLoS One. 2014 Sep 29;9(9):e103909. doi: 10.1371/journal.pone.0103909. eCollection 2014.

Reference Type DERIVED

PMID: 25264877 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IKPD 03-02

Identifier Type: -

Identifier Source: org_study_id